The SynTheTic Miracle

INVESTORS REPORT

The Revolutionary Flu Cure Set to Inject a 25-Fold Boost into Your Portfolio

File Number

File Type Confidential Open Access

0 7 5 2 4 1 9 9 2 0

The Synthetic Miracle:The Revolutionary Flu Cure Set to Inject a

250-Fold Boost into Your Portfolio

Dear Nova-X Report Reader,

Weve all seen the headlines.

The flu has made its annual visit to the U.S., reacquainting itself with your kids, spouse, parents, friends, and co-workers.

But this strain has been especially nasty, resulting in shortages of the very vaccines that might have moderated its effects.

One of my colleagues here - an editor with a young son - finally got his just last week - only because he stubbornly went to the same Rite-Aid every single morning for an entire week.

Im sure you have similar stories you could share.

When you think about it, this years flu season illustrates one of the great ironies of our time.

Although advances in medical technology have enabled us to create the vaccines that so far have kept the yearly viral visit in check, the reality is that those advances have been leapfrogged by global travel, an advancement that makes a pandemic more likely than ever before.

Fortunately, there is an answer - an innovation that savvy investors can play for windfall profits. Im going to show you how to grab those profits for yourself.

IMMEDIATE ATTENTION REQUIREDFor the most recent and up-to-date information

please visit www.moneymappress.com

Investors ReportFrom: Michael A. Robinson For: Nova-X Report Subscribers

the NOva-X RepORt Investors Report

2

But first we need to really understand the challenge at hand.

Let me show you what I mean.

At the start of each flu season, I literally count the days until I see the first mention of the Spanish Flu pandemic of 1918. I understand the attention it gets: Not only was it the worst flu outbreak in modern times, it is thought to have killed between 20 million and 50 million people.

By that standard, the SARS crisis of 2003 was a drop in the bucket.

It killed less than 1,000 people around the world. But it cost a fortune. The World Bank estimates the total hit to the global economy at some $33 billion.

No wonder health officials urge us to get flu shots...

Then came the vaccines - which, as it turns out, are actually like a page from history. The technology is decades old. Many vaccines stem from portions of viruses grown in chicken eggs - not exactly cutting-edge tech.

But the new generation of flu vaccines Im going to show you right now will change that.

They are cutting-edge tech. And they will help checkmate the advantages that global travel had granted to the flu virus - restoring balance in the process.

These new vaccines are synthetic, meaning they stem from fragments of manmade DNA. In essence, they are programmed to fight the flu or other designated diseases.

I see this as disruptive technology that will turn the $30 billion vaccine market inside out. Besides the flu, firms in this space are working on synthetic vaccines for leukemia, HIV, malaria, hepatitis, and cancer.

Yet one company shines above the rest. Im talking about Inovio Pharmaceuticals Inc. (NYSE: INO)

Inovio has great science. Thats why the firm has received millions in backing for its anti-malaria vaccine from a group affiliated with Bill and Melinda Gates.

thE NOVA-X REpORt Investors Report

3

Inovio also is working on a synthetic universal flu vaccine. And its other projects include, but arent limited to, vaccines for leukemia and cervical cancer. And it has another hook in the market. Its a novel process of giving injections known as electroporation.

In laymens terms, electroporation works like this: the patient receives the synthetic vaccine via an injection. But heres the secret sauce as the shot is given, the patient also receives a short electric pulse.

This burst of electricity causes cell membranes to open briefly to accept the DNA rather than try to fight it as a foreign substance. In turn, those cells produce antigens that tell the immune system to fight the targeted disease.

Not only is this great science, but I think it will work as a strong sales hook for future deals.

Not long ago, I had dinner with CEO and co-founder J. Joseph Kim. Hes an award-winning scientist and former vaccine exec at Merck & Co. Inc. (NYSE:MRK). And he studied under one of the towering giants of biotech, Robert Langer, a distinguished professor at MIT.

When I had dinner, Kim was largely unknown outside the synthetic vaccine sector of the biotech industry.

But he recently snagged a deal with Roche Holding AG (OTC: RHHBY) that could be worth $422.5 million.

And now Kim firmly believes his companys stock is undervalued at under $2 share.

I agree...

Fact is, Kim now has the chance to line up similar arrangements with other Big Pharma players that could net another $800 million or even more.

Were talking a deal pipeline that could be worth revenues of $1.2 billion for a firm with a market cap of just $480 million... and a firm that still has no products on the market.

the NOva-X RepORt Investors Report

4

We met for dinner at Bix, one of San Franciscos swankier restaurants, located on the edge of the Financial District.

As I listened to Kim update me over a meal of steak and crab rolls, I couldnt help but be struck by how much momentum Inovio has built up in such a short amount of time.

For Inovio and the entire synthetic vaccine space that could be worth some $30 billion in the next few years the Roche deal was nothing short of a game changer...

But dont take my word for it. During a conference call following the Roche news, industry analysts on the line all but openly applauded.

Under the deal, Inovio is granting Roche the exclusive rights to just two products still in the early, investigative stages of clinical trials. The licenses cover synthetic vaccines designed to treat prostate cancer (INO 5150) and hepatitis B (INO 1800).

Roche also gains the non-exclusive rights to Inovios patented electroporation process to deliver the vaccines.

Inovio has several other drugs involved in clinical trials that I believe will draw more ventures with Big Pharma if not an outright takeover offer.

Under the Roche deal, the drug giant immediately funds Inovio with $10 million. Inovio becomes eligible for the rest of the money as it hits key milestones on the road to FDA approval for those two products.

Moreover, Roche also takes over financing for both drug programs. It will continue to fund them from the current Phase I trials through Phase III and into full commercialization.

But Kim is quick to point out that hes free to pursue similar arrangements with its drug candidates for other forms of cancers as well as HIV and additional infectious diseases.

Roche wasnt the only player interested in those products, Kim told me. We had parallel discussions with other well-known names in Big Pharma.

thE NOVA-X REpORt Investors Report

5

I dont want to diminish the impact of this deal because it is our first one of this magnitude and approach. But these were early stage products. We were able to keep our lead programs intact.

The analogy I would use is that we traded away a couple of our young draft picks but we have many more coming behind those.

As a result, Kim says INO still has plenty of room to run. He bases that on a comparison with a biotech firm that trades at more than 25 times that of Inovio.

Alnylam Pharmaceuticals Inc. (NasdaqGS:ALNY) also is an early-stage biotech firm. It is focused on creating orphan drugs to treat serious diseases.

From a scientific standpoint, the two firms are mirror images of each other. Inovio is focused on synthetic DNA while Alnylam targets therapies based on RNA interference.

DNA contains genetic instructions needed for the bodys proper functioning. RNA on the other hand, is involved in protein synthesis and also in transmitting genetic instructions.

From the standpoint of market cap and share price, the two couldnt be more different.

With a market cap of more than $4 billion, ALNY trades at $53 a share despite the fact that it is losing money and has negative cash flow. So even if INO traded at just 20% of the value of ALNY, that would mean a stock price of around $10.50 a share, for a gain of roughly 400%.

We have a higher upside and a lower market cap, Kim says. Certainly that bodes very well our shareholders right now and for those in the future.

Ive watched Inovio and its progress for the last several months. With the Roche deal, it has cleared a major hurdle for me as a trader stable cash flow. I believe Inovio has a huge upside ahead.

WEBNVX1113-203

Copyright 2007-present, Money Map Press, 16 W. Madison Street, Baltimore, MD 21201 Phone: 888.384.8339 or 410.226.2069

All rights reserved. Money Map Press provides its members with unique opportunities to build and protect wealth, globally, under all market conditions. The executive staff, research department and editors who contribute to Money Map Press recommendations are proud of our history and reputation. We believe the advice presented to our subscribers in our published resources and at our meetings and seminars is the best and most useful avail-able to global investors today. The recommendations and analysis presented to members is for the exclusive use of members. Copying or disseminating any information published by Money Map Press, electronic or otherwise, is strictly prohibited. Members should be aware that investment markets have inherent risks and there can be no guarantee of future profits. Likewise, past performance does not assure future results. Recommendations are subject to change at any time, so members are encouraged to make regular use of the website and pay special attention to Money Map Press updates sent out via e-mail. The publishers, editors, employees or agents are not responsible for errors and/or omissions.

Privacy NoticeYou and your family are entitled to review and act on any recommendations made in this document. All Money Map Press publications are protected by copyright. No part of this report may be reproduced by any means (in-cluding facsimile) or placed on any electronic medium without written permission from the publisher. Information contained herein is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. Money Map Press expressly forbids its writers from having a financial interest in any security recommended to its read-ers. All Money Map Press employees and agents must wait 24 hours after an Internet publication and 72 hours after a print publication is mailed prior to following an initial recommendation. Money Map Press does not act as a personal investment advisor, nor does it advocate the purchase or sale of any security or investment for any specific individual. Investments recommended in this publication should be made only after consulting with your investment advisor, and only after reviewing the prospectus or financial statements of the company.

Money Map Press 16 W. Madison Street Baltimore, MD 21201 888.384.8339 or 410.226.2069

NOTE: Money Map Press is not a broker, dealer or licensed investment advisor. No person listed here should be considered as permitted to engage in rendering personalized investment, legal or other professional advice as an agent of Money Map Press. Money Map Press does not receive any compensation for these services. Additionally, any individual services rendered to subscribers by those mentioned are considered completely separate from and outside the scope of services offered by Money Map Press. Therefore if you choose to contact anyone listed here, such contact, as well as any resulting relationship, is strictly between you and them.

Please Note: From time to time, Money Map Press will recommend stocks or other investments that will not be included in our regular portfolios. There are certain situations where we feel a company may be an extraordinary value but may not necessarily fit within the selection guidelines of these existing portfolios. In these cases, the recommendations are speculative and should not be considered as part of Money Map Press philosophy.

Also, by the time you receive this report, there is a chance that we may have exited a recommendation previously included in our portfolio. Occasionally, this happens because we use a disciplined selling strategy with our investments, meaning that if a companys share price falls below a certain price level, we immediately notify our subscribers to sell the stock.